← All trials
NCT07076641
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2025
- Primary completion
- Jul 30, 2027
- Completion date
- Jul 30, 2027
- First posted
- Jul 22, 2025
- Last posted
- Jul 22, 2025
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GCS Ramsay Santé pour l’Enseignement et la RechercheLead sponsor
- EURAXI PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.